REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|February 1, 2022
Daily OTC Pearl: OptiBalance
Author(s)Saro Arakelians, PharmD
OptiBalance is a probiotic that helps at the start of menstruation to maintain a healthy balance.
Advertisement
OTC/Lifestyle Pearl of the Day: OptiBalance
Indication: OptiBalance is a probiotic that is used to create a healthy vaginal flora.
Insight:
- OptiBalance should be taken for 10 days for 30 days of balance with vH essentials OptiBalance Maintenance women's probiotic with prebiotic supplement.
- Take 1 capsule daily for 10 days to last for 30 days of support for a healthy vagina.
- OptiBalance helps at the start of the period to maintain a healthy balance of bacteria and yeast and prevent common vaginal pH imbalances.
- Contains clinically studied L. rhamnosus and L. acidophilus with lactoferrin (prebiotics) for feminine health and balance.
- Take 1 capsule preferably between meals for 10 consecutive days each month. Starts to work in 7 days
- No refrigeration needed. OptiBalance is gluten-free but may contain dairy.
- Clinical studies show that OptiBalance can restore a healthy balance by day 15 when taken as directed.
- This healthy ecosystem can help lessen common vaginal complaints.
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5